The development of specific, effective, and safe treatments for glaucoma patients, capable of reducing intraocular pressure and providing neuroprotection, constitutes an unmet medical need and is the main objective of the recently awarded project, coordinated between IQAC-CSIC and UB, entitled: “Next-generation lipid nanoparticles with self-assembled peptides for dual drug encapsulation: a step beyond biocompatible drug delivery systems for glaucomatous neurodegeneration”. The project, which will be carried out at IQAC-CSIC, will focus on the design and synthesis of self-assembled structures based on amphiphilic peptides (APs) for drug delivery to ocular tissues. APs, characterized by a structure with differentiated hydrophilic and hydrophobic components, have the ability to self-assemble in aqueous solution to form nanostructures that enable the encapsulation of poorly soluble drugs in aqueous solutions. Self-assembled APs, with the capacity to specifically target retinal ganglion cells, will improve the bioavailability of poorly soluble drugs in ocular tissues.
Enfermedad Archives
Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients
Glaucoma is one of the leading causes of irreversible blindness. Its usual treatment relies on eye drops that can cause systemic side effects due to drug diffusion throughout the body. Furthermore, these therapies have limitations in efficacy and low adherence. The GLAUxIS project proposes an innovative solution based on photoswitchable beta-blockers activated by visible light directly in the eye. This strategy allows for precise control of drug activity in space and time, achieving a reduction in intraocular pressure and avoiding adverse effects in other organs. Through the GLAUxIS project, we aim to offer society a glaucoma treatment using safer, more effective, and patient-centered therapies.